Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical relapse compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with no treatment (low certainty).
1 finding from 1 review
RR 0.71 [0.46, 1.1]
110 participants
Low
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes clinical relapse compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Sulphasalazine showed no clear difference in clinical relapse compared with placebo (low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review